Phase 3 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have been diagnosed with early-stage non-small cell lung cancer (NSCLC), specifically stage IA3 or IB, confirmed by a pathology report — most tumor types are allowed except those containing small-cell features.
• You have had surgery to completely remove the tumor with no cancer left at the edges (called a "clear margin" surgery), and the surgery involved removing at least one lobe of the lung, unless your tumor was 2 cm or smaller, in which case a smaller surgery may be acceptable.
• During or after surgery, enough lymph node samples were taken and examined to meet specific medical standards for checking whether cancer has spread.
• Your tumor tested positive for a protein called PD-L1, with a score of 50% or higher, using an approved lab test — this can be from your surgical or biopsy sample.
• Your tumor does not have certain specific gene changes (EGFR exon 19 deletion, L858R mutation, or ALK fusion) — note that purely squamous-type tumors do not need this testing.
• You are enrolling in the trial no sooner than 21 days and no later than 77 days after your surgery.
• Your doctor has determined you have sufficiently recovered from your surgery.
• You have not received any cancer treatment (chemotherapy, immunotherapy, etc.) before or after surgery for this lung cancer diagnosis.
• You are 18 years of age or older.
• You are well enough to carry out basic daily activities, based on a standard health performance scale (confirm with trial site).
• Your blood counts and organ function (including white blood cells, platelets, liver, and kidneys) meet minimum levels based on recent lab tests (confirm with trial site for exact values).
• If you are a woman who could become pregnant, you have had a negative pregnancy test within 7 days before enrolling.
• If you have HIV, you are on effective treatment and your virus levels are undetectable within the past 6 months.
• You do not have an active hepatitis B or hepatitis C infection (confirm with trial site if you have a history of either).
• If you have a history of heart problems, your heart function is assessed as stable enough to participate (confirm with trial site).
• You may still be eligible if you have had a different cancer in the past or present, as long as it is unlikely to interfere with this trial (confirm with trial site).

Who may not be able to join:

• You have a serious ongoing illness, uncontrolled infection, significant heart failure, unstable chest pain, or irregular heartbeat that is not well controlled.
• You currently have lung inflammation (pneumonitis), have had it in the past and needed steroid treatment for it, or have a history of a chronic lung scarring condition called interstitial lung disease (ILD).
• You have an active autoimmune disease (where your immune system attacks your own body) that has needed systemic medical treatment within the last 2 years — note that simple hormone replacement therapies (like thyroid or insulin) do not count as systemic treatment.
• You have had a severe allergic reaction (grade 3 or higher) to the study drug, atezolizumab, or any of its ingredients.
• You have received a live vaccine (such as measles, mumps, rubella, chickenpox, yellow fever, or BCG) within 30 days before enrolling.
• You have previously had a bone marrow, stem cell, or solid organ transplant from another person.
• You have been taking corticosteroids (such as prednisone) at a dose greater than 10 mg per day, or other immune-suppressing medications, within 14 days before enrolling — some exceptions apply for inhaled, topical, or low-dose replacement steroids (confirm with trial site).
• You are currently pregnant or breastfeeding, as the study drug may be harmful to a developing baby.
• You have an active infection that requires treatment with antibiotics or other systemic medications.
• You have active hepatitis B or hepatitis C infection.

Important: Always verify eligibility with the trial site directly before applying.